Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
Why Emergent BioSolutions Popped by Over 4% Today
05:35pm, Friday, 12'th Nov 2021
The company has given 250 million reasons why investors should buy its stock.
See Why Emergent BioSolutions Stock Plunged 37% On Friday?
04:24pm, Friday, 05'th Nov 2021
After a fiasco surrounding the contamination of COVID-19 vaccine doses in its facilities, Emergent BioSolutions Inc's (NYSE: EBS) manufacturing deal with the US government has come to an end. CEO Bo
Emergent Biosolutions shares plunge by more than 37% after U.S. cancels deal with Covid vaccine maker
11:06am, Friday, 05'th Nov 2021Emergent slumps as U.S. terminates COVID-19 vaccine manufacturing deal
07:31am, Friday, 05'th Nov 2021
Shares of Emergent BioSolutions Inc tumbled 15% on Friday, following the termination of a U.S. government contract to reserve capacity and expand manufacturing of third-party COVID-19 vaccines at its
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2021 Results - Earnings Call Transcript
10:39pm, Thursday, 04'th Nov 2021
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2021 Results - Earnings Call Transcript
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
06:30am, Monday, 18'th Oct 2021
GAITHERSBURG, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial r
GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogeni
What's Happening With Emergent Biosolutions Stock?
10:00am, Friday, 24'th Sep 2021
The stock price of Emergent Biosolutions, a specialty biopharmaceutical company, has seen a fall of 15% over the last twenty-one trading days, while it is down 42% year-t0-date. EBS stock has had a to
Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.
01:23pm, Tuesday, 21'st Sep 2021
DENVER--(BUSINESS WIRE)--Shuamn, Glenn & Stecker investigates Emergent BioSolutions, Inc. (NYSE: EBS).
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence
12:14pm, Wednesday, 15'th Sep 2021
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate
10:34am, Tuesday, 14'th Sep 2021
Emergent BioSolutions Inc (NYSE: EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and manufacture its COVID-19 vaccine candidate. Emergent
GAITHERSBURG, Md. and CALGARY, Alberta, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics today announced they have entered into a five-year contract
Emergent BioSolutions: Positive Outlook Despite Current Lawsuit
02:47am, Thursday, 02'nd Sep 2021
Emergent BioSolutions: Positive Outlook Despite Current Lawsuit
GAITHERSBURG, Md., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2
Emergent BioSolutions to Participate in Investor Conferences
04:05pm, Monday, 23'rd Aug 2021
GAITHERSBURG, Md., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following inves
